Cargando…

A randomized, phase III trial exploring the effects of neoadjuvant sequential treatment with steroidal (exemestane) and nonsteroidal (anastrozole) aromatase inhibitors on biomarkers in postmenopausal women with hormone receptor-positive locally advanced breast cancer

Detalles Bibliográficos
Autores principales:	Freedman, OC, Amir, E, Dranitsaris, G, Dowsett, M, Cole, DEC, Kahn, H, O'Malley, F, Verma, S, Clemons, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284919/ http://dx.doi.org/10.1186/bcr2316

Ejemplares similares

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.
por: Geisler, J., et al.
Publicado: (1996)

Efficacy of Exemestane in Korean Patients with Metastatic Breast Cancer after Failure of Nonsteroidal Aromatase Inhibitors
por: Lee, June Koo, et al.
Publicado: (2013)

Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer
por: Iaffaioli, R V, et al.
Publicado: (2005)

Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer
por: Iaffaioli, R V, et al.
Publicado: (2005)

Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women
por: Goss, Paul E, et al.
Publicado: (2007)

Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.
por: Zilembo, N., et al.
Publicado: (1995)

Identification and Quantification of Novel Major Metabolites of the Steroidal Aromatase Inhibitor, Exemestane
por: Luo, Shaman, et al.
Publicado: (2018)

Regulation of aromatase expression in breast cancer treated with anastrozole neoadjuvant therapy
por: GHIMENTI, CHIARA, et al.
Publicado: (2013)

Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action
por: Cairns, Junmei, et al.
Publicado: (2020)

Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole – of clinical importance?
por: Geisler, J
Publicado: (2011)

Bone Safety Profile of Steroidal Aromatase Inhibitor in Comparison to Nonsteroidal Aromatase Inhibitors in Postmenopausal Women with Breast Cancer: A Network Meta-Analysis
por: Chen, Shanshan, et al.
Publicado: (2022)

Inhibition of the Aromatase Enzyme by Exemestane Cysteine Conjugates
por: Teslenko, Irina, et al.
Publicado: (2022)

Anastrozole (Arimidex ™) – an aromatase inhibitor for the adjuvant setting?
por: Buzdar, A U
Publicado: (2001)

Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC
por: Young, Patricia A., et al.
Publicado: (2021)

Impact of nonsteroidal aromatase inhibitors on steroid profile in a Chinese population
por: Xing, Yanyi, et al.
Publicado: (2017)

Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early‐Stage Breast Cancer
por: Cairns, Junmei, et al.
Publicado: (2021)

Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal aromatase inhibitors in postmenopausal women with early breast cancer: a prospective cohort study
por: Wang, Xue, et al.
Publicado: (2020)

CORRIGENDUM to “Steroidal aromatase inhibitors have a more favorable effect on lipid profiles than nonsteroidal aromatase inhibitors in postmenopausal women with early breast cancer: a prospective cohort study”
Publicado: (2020)

Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer
por: Anderson, T J, et al.
Publicado: (2002)

A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer
por: Iwata, Hiroji, et al.
Publicado: (2013)

Influence of Glutathione-S-Transferase A1*B Allele on the Metabolism of the Aromatase Inhibitor, Exemestane, in Human Liver Cytosols and in Patients Treated With Exemestane
por: Teslenko, Irina, et al.
Publicado: (2022)

Anastrozole-Induced Dermatitis: Report of a Woman with an Anastrozole-Associated Dermatosis and a Review of Aromatase Inhibitor-Related Cutaneous Adverse Events
por: Kim, Yoo Jung, et al.
Publicado: (2020)

Exemestane in the Adjuvant Treatment of Breast Cancer in Postmenopausal Women
por: Kittaneh, Muaiad, et al.
Publicado: (2011)

A Polymorphism at the 3′-UTR Region of the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor, Anastrozole, in Metastatic Breast Carcinoma
por: Liu, Lei, et al.
Publicado: (2013)

Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer
por: Makhlin, Igor, et al.
Publicado: (2022)

Comparative effectiveness of tamoxifen, toremifene, letrozole, anastrozole, and exemestane on lipid profiles in breast cancer patients: A network meta-analysis
por: He, Tao, et al.
Publicado: (2020)

The beneficial androgenic action of steroidal aromatase inactivators in estrogen-dependent breast cancer after failure of nonsteroidal drugs
por: Gao, Lanyang, et al.
Publicado: (2019)

Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience
por: Li, Yi, et al.
Publicado: (2020)

Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer
por: Yamamoto, Yutaka, et al.
Publicado: (2013)

Correlation Between Anthropometric Measures and Biomarker Changes After Neoadjuvant Therapy With Tamoxifen or Anastrozole in Postmenopausal Women With Breast Cancer
por: Cintra, Karine A., et al.
Publicado: (2010)

Exemestane potency is unchanged by common nonsynonymous polymorphisms in CYP19A1: results of a novel anti‐aromatase activity assay examining exemestane and its derivatives
por: Peterson, Amity, et al.
Publicado: (2017)

Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer
por: Aktas, Bilge, et al.
Publicado: (2016)

Effects of tamoxifen and exemestane on cognitive function in postmenopausal patients with breast cancer
por: Lee Meeuw Kjoe, Philippe R, et al.
Publicado: (2023)

SUN-125 Phase Ib Study of Dual Therapy with an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women with Advanced Non-Small Cell Lung Cancer
por: Young, Patricia A, et al.
Publicado: (2020)

Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers.
por: Yates, R. A., et al.
Publicado: (1996)

Rethinking the combination treatment of fulvestrant and anastrozole for metastatic breast cancer: an integrated reanalysis of aromatase–estrogen receptor axis
por: Huang, Xing
Publicado: (2019)

Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study
por: van Nes, J. G. H., et al.
Publicado: (2012)

Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
por: Sato, Nobuaki, et al.
Publicado: (2019)

Developing a prediction model for benefit from fulvestrant in heavily pretreated metastatic breast cancer patients
por: Amir, E, et al.
Publicado: (2009)

An Exemestane Derivative, Oxymestane-D1, as a New Multi-Target Steroidal Aromatase Inhibitor for Estrogen Receptor-Positive (ER(+)) Breast Cancer: Effects on Sensitive and Resistant Cell Lines
por: Amaral, Cristina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3oli4l2i2bc9stisslc4531o8s